State of New Jersey Common Pension Fund D Raises Stock Holdings in LivaNova PLC (NASDAQ:LIVN)

State of New Jersey Common Pension Fund D increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 38.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,539 shares of the company’s stock after purchasing an additional 11,782 shares during the period. State of New Jersey Common Pension Fund D owned 0.08% of LivaNova worth $2,235,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Driehaus Capital Management LLC grew its stake in shares of LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock valued at $29,824,000 after purchasing an additional 213,749 shares during the last quarter. Perceptive Advisors LLC raised its position in LivaNova by 48.5% during the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock worth $24,340,000 after buying an additional 145,000 shares during the last quarter. Great Lakes Advisors LLC acquired a new stake in shares of LivaNova in the 2nd quarter worth $16,614,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of LivaNova by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company’s stock valued at $1,736,000 after acquiring an additional 1,980 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new position in shares of LivaNova during the second quarter worth about $1,103,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on LIVN shares. Mizuho reduced their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th. Robert W. Baird raised their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, The Goldman Sachs Group initiated coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective for the company. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $69.17.

LivaNova Price Performance

LivaNova stock opened at $52.32 on Friday. The firm has a market capitalization of $2.84 billion, a PE ratio of 127.57 and a beta of 1.01. LivaNova PLC has a 52 week low of $42.75 and a 52 week high of $64.47. The firm’s 50-day simple moving average is $51.56 and its 200 day simple moving average is $52.98. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.